Galatea Bio Secures $25M to Develop Global Biobank and Enable Precision Health at Scale for All

Building the world's largest biobank with data from global populations to accelerate biomarker and drug discovery and development of next-generation diagnostics.

Secured $25M in funding from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI Ventures, AME Cloud, Alexandria, Founders Collective, Stanford President's Fund, and HBM Genomics.

MIAMI, March 27, 2025 (GLOBE NEWSWIRE) -- Galatea Bio, a leader in AI-driven genomic research and clinical genetic testing has secured $25 million in funding to drive discoveries in next-generation genetic analysis, biomarker discovery, and multi-omics disease modeling. Committed to enabling precision health at scale for all, Galatea Bio is expanding its Biobank of the Americas into the Galatea Global Biobank, a landmark initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry, to unlock new insights into human health.

Founded in 2021 by Carlos D. Bustamante, Ph.D., a world-renowned population geneticist, Stanford faculty member, and alumni of the investigator program at Chan Zuckerberg Biohub, Galatea Bio is addressing one of the most pressing challenges in genomics - the need for comprehensive, predictive datasets from global populations. To date most genomics datasets are based on patients with European ancestry. To achieve its mission, the company develops novel data science tools and operates a College of American Pathologists (CAP)-accredited biobank to store patient samples from collaborating medical centers, and a CAP-accredited clinical genetic testing laboratory.

"Galatea Bio envisions a future where healthcare is accessible to all and tailored to each individual's genetic makeup and predicted future disease trajectory," said Bustamante, CEO and President, Galatea Bio. "By analyzing a broad spectrum of genetic, longitudinal health records, and real-world evidence data from multi-ancestry populations, Galatea is generating new insights into the biological processes that underlie health and disease - a process we are committed to accelerating. This work represents a critical step toward truly personalized healthcare on a global scale."

Galatea has ...